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Despite high tumour response rates to platinum-based chemotherapy in ovarian cancer survival is poor due to the emergence of
drug resistance. Mechanistic studies in clinical material have been hampered by the unavailability of sensitive methods to detect the
critical drug-induced effects in individual cells. A modification of the single cell gel electrophoresis (comet) assay allows the sensitive
detection of DNA interstrand crosslinking in both tumour and normal cells derived directly from clinical material. Tumour cells
isolated from 50 ovarian cancer patients were treated ex vivo with 100mM cisplatin for 1h and crosslink formation and repair
(unhooking) measured. No significant difference in the peak level of crosslinking in tumour cells was observed between patients who
were either newly diagnosed or previously treated with platinum-based therapy, or between tumour and mesothelial cells from an
individual patient. This indicates no difference in cellular mechanisms such as drug transport or detoxification. In contrast, the
percentage repair (unhooking) of DNA interstrand crosslinks was much greater in the group of treated patients. At 24h in the 36
newly diagnosed patient tumour samples, only one gave 450% repair and 23 gave o10% repair; however, 19 out of 22 treated
patient samples gave 410% repair and 14 showed 450% repair. The estimated median difference (newly diagnosed minus treated)
was  52 (95% CI  67 to  28), and the P-value from a Mann–Whitney test was o0.001. In eight patients, it was possible to obtain
tumour samples prior to any chemotherapy, and also on relapse or at interval debulking surgery following platinum-based
chemotherapy. In these patients, the mean % repair prior to therapy was 2.85 rising to 71.23 following treatment. These data
demonstrate increased repair of DNA interstrand crosslinks in ovarian tumour cells following platinum therapy which may contribute
to clinical acquired resistance.
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The lifetime risk of a woman developing ovarian cancer is 1 in 70
and around two thirds of these patients present with advanced
disease (Ozols et al, 2001). The standard first line treatment for
ovarian cancer is cytoreductive surgery followed by carboplatin
alone or more commonly in combination with paclitaxel (du Bois
et al, 2005). This treatment results in a complete response in the
majority of women; however, most responding patients eventually
relapse with disease that becomes resistant not only to platinum
compounds, but also to a wide range of other chemotherapeutic
agents (Salzberg et al, 2005). The prognosis for women with
relapsed ovarian cancer remains poor with a 5-year survival of
25% (Colombo et al, 2006). A greater understanding of the
mechanisms underlying drug resistance could lead to measures to
overcome it and improve survival.
Resistance to chemotherapeutic agents such as carboplatin can
be intrinsic or acquired (Perez, 1998). Intrinsic resistance is
present at the time of diagnosis, and the patient fails to respond to
first line chemotherapy. Studies in ovarian cancer cell lines have
shown that acquired resistance to platinum drugs can be multi-
factorial, consisting of mechanisms which include altered drug
transporter proteins (Kelland, 2000), increased drug inactivation,
for example, by binding of drugs to glutathione (Kelland, 2000),
evasion of apoptosis by mutation of genes such as p53 (Manic et al,
2003) and enhanced ability to repair DNA damage such as by
upregulation of ERCC1 (Ferry et al, 2000). It is still unclear,
however, which of these contribute most to acquired drug
resistance in the clinical setting. Studies in clinical material have
been hampered by the unavailability of sensitive methods to detect
the critical drug-induced effects in individual cells.
The cytotoxicity of carboplatin and cisplatin results from the
formation of platinum-DNA adducts which include monoadducts,
intrastrand crosslinks, interstrand crosslinks (ICLs) and DNA-
protein crosslinks (Zwelling et al, 1979; Comess and Lippard,
1993). Intrastrand crosslinks constitute the majority (480%) of
lesions formed on cellular DNA and these distorting lesions are
repaired by nucleotide excision repair (Fichtinger-Schepman et al,
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s1995). ICLs, which link the two complementary strands of DNA
together, comprise less than 5% of the total lesions on DNA but are
highly cytotoxic and difficult to repair (McHugh et al, 2001).
We have previously demonstrated that a modification of the
single cell gel electrophoresis (comet) assay (Spanswick et al, 1999)
can be used successfully in the clinical setting to detect and
quantify the levels of ICLs in patient lymphocytes and tumour cells
at pharmacologically relevant doses of bifunctional alkylating
agents (Hartley et al, 1999; Webley et al, 2001; Spanswick et al,
2002; Corrie et al, 2005). The method has also been used to
measure cisplatin-induced ICLs in vitro (De Silva et al, 2002). In
this study, we have used the method to compare the formation and
repair (unhooking) of ICL’s following ex vivo exposure to cisplatin
in tumour cells and normal cells isolated from ovarian cancer
patients who were either newly diagnosed, or had been previously
treated with platinum-based chemotherapy.
MATERIALS AND METHODS
Patient population
Ethics approval was gained from the Joint UCL/UCLH Committee
on the Ethics of Human Research. Ovarian cancer patients
receiving treatment between February 2001 and February 2006
were recruited to take part in this study. Solid tumour tissue
or ascitic fluid was obtained from 50 ovarian cancer patients
aged between 45 and 91 years. Samples were obtained at diagnosis,
interval debulking surgery (IDS) or at relapse. In some
cases, paired samples were obtained at diagnosis and IDS, or at
relapse.
Preparation of tumour and non-tumour cells from clinical
material
Ascitic fluid was aliquoted into plastic 50ml conical tubes and
spun at 200 g for 5min. Cell pellets were resuspended in
Dulbecco’s modification of Eagle’s medium (DMEM) containing
10% fetal calf serum (FCS) and 2mM glutamine, and seeded into
large tissue culture flasks. All cells were maintained in a
humidified atmosphere with 5% CO2 at 371C. After 1h, the entire
volume of tissue culture medium in each flask, containing
unattached cells was transferred into a fresh large tissue culture
flask, and DMEM (with FCS and glutamine) was replaced in the
original flasks. Non-tumour cells generally attached to the plastic
surface within the first hour, whereas tumour cells required a
longer period of incubation. Tumour cells also required a longer
period of time to detach in response to trypsin, compared to the
non-tumour, mesothelial cells. Further purification of the tumour
samples was achieved by trypsinisation until the contaminant
mesothelial cells were seen to detach, while the tumour cells
remained in situ.
In sterile conditions, primary tumour was finely dissected and
flushed with DMEM containing 10% FCS and 2mM glutamine, to
produce a single cell suspension, which was seeded into large
tissue culture flasks.
Immunocytochemistry
Antibodies to CA125 (Novocastra, Newcastle, UK) and AUA1
(Skybio, Bedfordshire, UK) which stain ovarian tumour cells and
not mesothelial cells, and to Calretinin (Zymed, Cambridge, UK)
and CK5 which stain mesothelial cells but not ovarian cancer cells,
were used to differentiate the two cell types in cytospin
preparations using standard immunocytochemical techniques.
Analysis was performed on the same cell population that was
treated with cisplatin.
Treatment of tumour and non-tumour cells ex vivo with
cisplatin
Primary cultures of tumour and mesothelial cells were trypsinised
and seeded at a concentration of 5 10
4 cells per ml into 6-well
plates. Cells were left to attach overnight. Half of the samples were
non-drug-treated controls, the other half were drug treated with
100mM cisplatin (David Bull Laboratories, Australia), diluted in
DMEM, for 1h at 371C in a humidified atmosphere with 5% CO2.
The cisplatin was removed and fresh DMEM with 10% FCS and
2m M glutamine was added to the samples. Immediately after drug
treatment, a drug treated and a non-drug-treated control sample
were trypsinised, centrifuged at 200g for 5min, then resuspended
in FCS with 10% DMSO. Samples were then frozen in a polystyrene
box within a  801C freezer. This procedure was repeated 4.5, 9, 24
and 48h after drug exposure.
Single cell suspensions were prepared at a cell density of 5 10
4
cells per ml. Cells were treated with 100mM cisplatin in DMEM at
371C, 5% CO2. After exposure, cell samples were centrifuged at
200g for 5min, and then resuspended with DMEM with 10% FCS
and 2mM glutamine. Immediately after drug treatment, a drug
treated and a non-drug-treated control samples were trypsinised,
centrifuged at 200g for 5min, and then resuspended in FCS with
10% DMSO. Samples were then frozen in a polystyrene box within
a  801C freezer. This procedure was repeated 4.5, 9, 24 and 48h
after drug exposure.
Measurement of DNA interstrand crosslinking using the
single cell gel electrophoresis (comet) assay
The details of the modified single cell gel electrophoresis (comet)
assay to measure DNA ICLs are described in detail elsewhere
(Hartley et al, 1999; Spanswick et al, 1999). All procedures
performed on the single cell suspension sample were carried out
on ice and in subdued lighting. All chemicals used were obtained
from Sigma Chemical Co. (Poole, UK) unless otherwise stated.
Immediately before analysis, cells were irradiated (12.5Gy,
2.35Gymin
 1) to deliver a fixed number of random DNA strand
breaks. After embedding cells in 1% agarose on a precoated
microscope slide, the cells were lysed for 1h in lysis buffer (100mM
disodium EDTA, 2.5 M NaCl, 10mM Tris-HCl pH 10.5) containing
1% Triton X-100 added immediately before analysis, and then
washed for 1h in distilled water, changed every 15min. Slides were
then incubated in alkali buffer (50mM NaOH, 1mM disodium
EDTA, pH 12.5) for 45min followed by electrophoresis in the same
buffer for 25min at 18V (0.6Vcm
 1), 250mA. The slides were
finally rinsed in neutralising buffer (0.5 M Tris-HCl, pH 7.5) and
then in saline.
After drying, the slides were stained with propidium iodide
(2.5mgml
 1) for 30min and then rinsed in distilled water. Images
were visualised using a NIKON inverted microscope with a high-
pressure mercury light source, 510–560nm excitation filter and
590nm barrier filter at  20 magnification. Images were captured
using an online CCD camera and analysed using Komet Analysis
software (Kinetic Imaging, Liverpool, UK). For each duplicate
slide, 25 cells were analysed. The tail moment for each image was
calculated using the Komet Analysis software as the product of the
percentage DNA in the comet tail and the distance between the
means of the head and tail distributions, based on the definition of
Olive et al (1990). Crosslinking was expressed as the percentage
decrease in tail moment compared to irradiated controls calculated
by the formula:
%decreaseintailmoment ¼ 1  
TMdi   TMcu
TMci   TMcu
 
 100
where Tmdi is the tail moment of drug-treated irradiated sample,
TMcu the tail moment of untreated, unirradiated control and TMci
the tail moment of untreated, irradiated control.
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sStatistical analysis
Statistical analyses were performed in Minitab version 13.32.
Probability plots were observed to determine whether the three
variables (percentage decrease in tail moment, the paired
difference in tail moment decrease between tumour and mesothe-
lial cells, and percentage repair at 24h) were normally distributed.
If they were, unpaired or paired t-tests were performed, and the
mean difference with 95% CI obtained. If the distributions were
not normal, the median was used as the measure of central
tendency and the Mann–Whitney non-parametric test used to
examine differences between groups. Minitab also provides an
estimate of the median difference between newly diagnosed and
treated patients, with 95% CI.
RESULTS
Measurement of DNA interstrand crosslinking in ovarian
tumour cells treated ex vivo with cisplatin using the single
cell gel electrophoresis (comet) assay
Samples were obtained from 36 patients prior to any platinum-
based chemotherapy (Table 1A) and from 22 patients following
platinum-based chemotherapy (Table 1B). In eight cases (patients
3, 17, 18, 27, 34, 39, 44 and 47) paired samples were obtained at
diagnosis, and at relapse or IDS following platinum-based
chemotherapy. Either primary tumour cell cultures from drained
ascitic fluid or single cell suspensions from ovarian tumours from
surgery were obtained. Immunohistochemistry was used to
determine the purity of the tumour cell population. In all cases,
the cell sample contained 480% tumour cells and in the majority
of cases it was 490%.
Cells were treated with cisplatin for 1h at 100mM. This dose was
determined from pilot experiments in human ovarian cancer cell
lines to give an optimal level of DNA ICLs as determined by the
single cell gel electrophoresis (comet) assay. Following 1h
treatment cells were re-suspended in drug-free medium and
samples taken for measurement of DNA crosslinking at 9h (the
peak of crosslinking with cisplatin), 24 and 48h. DNA crosslinking
was expressed as the % decrease in tail moment compared to
control non-drug treated cells as previously described (Hartley
et al, 1999; Spanswick et al, 1999). Crosslink response curves for
patient samples 1 and 8 are shown in Figure 1. In the tumour cells
from patient 1 (Figure 1A) around 55% decrease in tail moment is
observed at the peak of crosslinking (9h). By 24h, the majority
(495%) of the crosslinks have been repaired or ‘unhooked’ from
the DNA. In contrast, in the cells from patient 8 (Figure 1B)
although the level of crosslinks at the peak is similar, very little
unhooking is observed at 24h (o10%) and the majority of
crosslinks persist at 48h.
Peak level of cisplatin-induced DNA interstrand crosslinks
in patient tumour and mesothelial cells
The peak (9h) level of DNA interstrand crosslinking was
determined in all patient tumour samples, following treatment
Table 1A Newly diagnosed patient characteristics
Patient number Age Treatment post sample FIGO stage Progression-free survival (months) Sample type
2 56 Carboplatin/paclitaxel 3c 455 Ascites
3 48 Carboplatin/paclitaxel 3c 15 Ascites
5 50 Carboplatin/paclitaxel 4 9 Ascites
6 57 Carboplatin/paclitaxel 4 20 Ascites
8 60 Carboplatin 3c 0 Ascites
9 78 Carboplatin 3c 12 Ascites
12 58 Carboplatin/paclitaxel 3c 17 Ascites
17 64 Carboplatin 3c 10 Ascites
18 63 Carboplatin/paclitaxel 4 12 Ascites
19 68 Carboplatin/paclitaxel 2c 413 Solid tumour
20 91 None Not known NA Ascites
21 65 Carboplatin/paclitaxel 3c 44 Solid tumour
23 74 Carboplatin/paclitaxel 3c 10 Ascites
24 63 Carboplatin/paclitaxel 3c 7 Ascites
25 50 Carboplatin/paclitaxel 2c 44 Solid tumour
26 63 Carboplatin/paclitaxel 3c 44 Solid tumour
27 54 Carboplatin/paclitaxel 3c 0 Ascites
28 45 Carboplatin/paclitaxel 3a 48 Solid tumour
29 77 Carboplatin 2b 46 Solid tumour
30 62 Carboplatin 1c 46 Ascites
32 62 Carboplatin 2b 47 Solid tumour
33 73 Carboplatin/paclitaxel 3c 47 Ascites
34 70 Carboplatin/paclitaxel 3c 9 Ascites
36 61 Carboplatin 1a 44 Solid tumour
37 54 None (too unwell) 3c 0 Ascites
38 64 Carboplatin/paclitaxel 3 3 Ascites
39 58 Carboplatin/paclitaxel 4 0 Ascites
40 63 Carboplatin/paclitaxel 3c 5 Ascites
42 87 Carboplatin 3c 46 Solid tumour
44 80 Carboplatin 3c 6 Ascites
45 76 Carboplatin 3c 44 Ascites
46 78 None (too unwell) 3c NA Ascites
47 77 Carboplatin (intraperitoneal) 3c 0 Ascites
48 66 Carboplatin/paclitaxel 4 43 Ascites
49 56 No data 3c No follow up Ascites
50 66 Carboplatin/paclitaxel 3c 44 Ascites
Abbreviation: NA¼not applicable.
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swith 100mM cisplatin. The data are presented in Figure 2 with the
newly diagnosed patients and those treated with platinum-based
chemotherapy shown separately. A high level of crosslinking was
observed in all the samples tested with the % decrease in tail
moment ranging from 30 to 81%. The mean level of crosslinking in
all samples was 60.54. The percentage decrease in tail moment was
normally distributed. The mean difference between the two groups
(newly diagnosed minus treated) is  2, with 95% CI  7 to 4. The
P-value from an unpaired t-test was 0.49, indicating no evidence of
a real difference.
In many of the samples derived from ascitic fluid, it was possible
to isolate mesothelial cells to act as a non-tumour direct
comparison within the same patient. Data for the matched samples
are shown in Figure 3. The paired difference between the
percentage decrease in tail moment (mesothelial minus tumour
cells for each patient) was normally distributed. In the 10 newly
diagnosed cases, the mean difference between tumour and control
cells was 3.5 (95% CI  3.7 to 10.7), with a P-value from a paired
t-test of 0.30. In the seven treated cases, the mean difference was
0.5 (95% CI  8.3 to 9.3), P-value of 0.90. Therefore, in each group,
there was no evidence of a difference between tumour and
mesothelial cells. These data demonstrate that tumour cells and
Table 1B Treated patient characteristics (IDS and relapse)
Patient number Age Treatment post sample FIGO stage PFI months Clinical Category PFS months Sample type
3 48 Carboplatin/paclitaxel 3c NA IDS 15 Solid tumour
15 51 Carboplatin/paclitaxel 4 NA IDS 436 Solid tumour
18 63 Carboplatin/paclitaxel 4 NA IDS 11 Solid tumour
34 70 Carboplatin/paclitaxel 3c NA IDS 9 Ascites
35 53 Etoposide 4 NA IDS 11 Solid tumour
43 69 Cisplatin/etoposide 3c NA IDS 0 Ascites
44 80 Carboplatin 3c NA IDS 46 Ascites
1 53 Carboplatin 4 24 46months
a 5 Ascites
4 59 Carboplatin 4 27 46months 9 Ascites
14 57 Topotecan 3c 8 46months 0 Ascites
7 68 Topotecan 3c 6 o6months
a 11 Ascites
10 71 Liposomal doxorubicin 3c 4 o6months 4 Ascites
11 56 Liposomal doxorubicin 3c 2 o6months 0 Solid tumour
13 75 Carboplatin/gemcitabine 4 0 o6months 0 Ascites
16 80 None
b 3c 0 o6months 0 Ascites
17 66 None 3c 3 o6months 0 Ascites
22 69 None
b 40 o6months 0 Ascites
27 54 None
b 3c 0 o6months 0 Ascites
31 49 Carboplatin/paclitaxel 3c 4 o6months 0 Ascites
39 58 Cisplatin/etoposide 4 0 o6months 46 Ascites
41 63 None
b 44 o6months 0 Ascites
47 77 None
b 3c 0 o6months NA Ascites
Abbreviations: IDS¼interval debulking surgery; NA¼not applicable; PFI¼platinum-free interval; PFS¼progression-free survival.
aClinical category of relapse determined by the
PFI is used to decide about likelihood of a response to further platinum-based chemotherapy.
bPatients relapsed on carboplatin chemotherapy.
0
20
40
60
80
100
0 6 12 18 24 30 36 42 48
Time (hours)
0
20
40
60
80
100
0 6 12 18 24 30 36 42 48
Time (hours)
%
 
d
e
c
r
e
a
s
e
 
i
n
 
t
a
i
l
 
m
o
m
e
n
t
%
 
d
e
c
r
e
a
s
e
 
i
n
 
t
a
i
l
 
m
o
m
e
n
t
Figure 1 Time course of DNA interstrand crosslink formation and repair
in human ovarian cancer cells from patient 1 (A)a n dp a t i e n t8( B) as deter-
mined by the single cell gel electrophoresis (comet) assay. Cells were treated
ex vivo with cisplatin for 1h at 100mM. The data points are the values from
two independent experiments and the lines are plotted through the mean.
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Figure 2 Level of DNA interstrand crosslinking at 9h following
treatment with 100mM cisplatin in tumour cells from 50 patients as
determined by the comet assay. Scatter plot of the percentage decrease in
tail moment in newly diagnosed patients, and those previously treated with
platinum-based chemotherapy. The horizontal lines indicate the mean value
in each group.
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smesothelial cells do not differ significantly in their uptake or
cellular metabolism of cisplatin thereby allowing similar levels of
DNA damage to occur.
Repair of cisplatin-induced crosslinks in patient tumour
cells
The ability of the tumour cells to repair the DNA ICLs produced by
cisplatin was determined from the crosslink response curves
produced for each patient sample. The level of crosslinking was
compared at 9 and 24h and the % repair at 24h calculated. These
data are shown in Figure 4. A highly heterogeneous response was
observed between the different patient samples ranging from no
repair to almost 100% repair at 24h. In some samples, the level of
crosslinking was even slightly higher at 24h than at 9h resulting in
a ‘negative’ % repair value. Strikingly, the response in the samples
from newly diagnosed patients was generally very different to that
in the samples from platinum-treated patients. In the 36 newly
diagnosed patients, only one gave a level of repair above 50% and
23 gave o10% repair. In contrast, 19 out of 22 previously treated
patients gave 410% repair and 14 showed 450% repair. The
mean % repair was 8.75 in the newly diagnosed patients compared
to that of 52.4 in the treated patients. Percentage repair at 24h was
not normally distributed. The estimated median difference (newly
diagnosed minus treated) is  52 (95% CI  67 to  28), and the
P-value from a Mann–Whitney test was o0.001. These results
show that the percentage repair was much greater in the group of
treated patients.
In the mesothelial samples, the repair response was more
homogeneous than in the matched tumour samples. The mean %
repair in the 17 mesothelial samples was 17.84±20.77
(18.82±24.41 in the 10 samples from newly diagnosed patients
and 16.43±15.9 in the seven samples from treated patients).
Repair of cisplatin-induced crosslinking in tumour cells
from the same patient before and after platinum-based
chemotherapy
In eight patients, it was possible to obtain tumour samples prior to
any chemotherapy, and also on relapse following platinum-based
chemotherapy. The % repair values for these patients are shown in
Figure 5. In four patients, the second sample was taken at IDS
(Figure 5A) and in the other four, the second sample was taken at
relapse following a treatment-free interval o6 months (Figure 5B).
These two clinically distinct groups showed similar changes. In five
out of the eight patients prior to chemotherapy the tumour cells
Newly diagnosed Treated
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Figure 3 DNA interstrand crosslinking at 9h following treatment with
100mM cisplatin in tumour cells and mesothelial cells isolated from the
same patient. Scatter plot shows the difference in the percentage decrease
in tail moment in newly diagnosed and previously treated patients. The
horizontal lines indicate the mean value in each group.
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Figure 4 Repair (unhooking) of cisplatin-induced DNA interstrand
crosslinking in the same tumour samples as Figure 2. Data are expressed as
the % repair at 24h compared to the peak level at 9h. A negative % repair
indicates that the level of crosslinking was higher at the 24h time point than
at the 9h point. Scatter plot of the percentage repair at 24h in newly
diagnosed and previously treated patients. The distributions are skewed, so
the horizontal lines indicate the median value in each group.
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Figure 5 Repair of cisplatin-induced DNA interstrand crosslinking in
tumour from eight patients where samples were taken both at initial
diagnosis and following platinum-based chemotherapy. In (A) the second
samples were taken at interval debulking surgery and in (B) the samples
were taken at relapse following a treatment-free interval o6 months.
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sdid not show any repair of crosslinks at 24h, and o30% repair at
24h was observed in the other three. In contrast, the tumour cells
following chemotherapy show extensive unhooking of crosslinks
in each case with % repair ranging from 28.1 to 95.4, with seven
of the eight samples showing 460% repair. In these eight patients,
the mean % repair prior to therapy was 2.85±13.59 rising to
71.23±20.12 following treatment.
DISCUSSION
The data presented here clearly demonstrate that, in tumour cells
isolated from 50 ovarian cancer patients, the peak level of DNA
interstrand crosslinking produced by the chemotherapeutic drug
cisplatin is very similar (mean 60.54±9.98), as determined by the
single cell gel electrophoresis (comet) assay. This is irrespective of
whether the tumour sample was from a newly diagnosed patient,
or one who had been treated with platinum-based chemotherapy.
This would indicate that any molecular mechanism of drug
resistance that has been evoked following chemotherapy does not
involve an ‘upstream’ mechanism (e.g., altered drug transport,
increased detoxification) which would prevent the drug from
reaching its cellular target, DNA. Similarly, tumour cells and
mesothelial cells from the same patient do not differ significantly
in their uptake or cellular metabolism of cisplatin thereby allowing
similar levels of DNA damage to occur.
The single cell gel electrophoresis (comet) assay allows DNA
interstrand crosslinking to be measured in clinical samples at
pharmacologically relevant doses of crosslinking drug. This can be
used to measure crosslinking in lymphocytes or solid tumour
material where samples are taken following treatment of patients
with drugs such as ifosfamide (Hartley et al, 1999), treosulfan
(Corrie et al, 2005) or antibody directed enzyme pro-drug therapy
(Webley et al, 2001). Alternatively, it can be used to measure
crosslink formation and repair in cells isolated from patients and
treated ex vivo with drug as in the present study, or as previously
demonstrated in myeloma plasma cells treated with melphalan
(Spanswick et al, 2002). In the latter study, myeloma cells from
chemotherapy naı ¨ve patients were all incapable of repairing
melphalan-induced crosslinks at 24h after the peak of formation.
Cells from melphalan resistant patients all showed significant
repair ranging from 42 to 100% repair at 24h. In the current study,
the repair of crosslinking was more heterogeneous in both the
newly diagnosed and treated patient populations but the overall
trend to increased repair of interstrand crosslinking was clearly
evident.
It should be noted that repair as measured by the comet assay is
really the ‘unhooking’ of one arm of the crosslink to release the
covalent linkage of the two strands of the double helix. This is the
first step in the complex molecular mechanism of repair of DNA
ICLs (McHugh et al, 2001) and the comet assay cannot determine if
the repair process has gone to completion and correctly restored
the integrity of both strands of the DNA. Mammalian cells
defective in the unhooking step of cisplatin interstrand crosslink
repair, as measured using the comet assay, include cells bearing
mutations in nucleotide excision repair (e.g., XPB, XPD, XPG,
ERCC1 and XPF) and homologous recombination (e.g., XRCC2
and XRCC3) (De Silva et al, 2002). Cells defective in ERCC1 are
highly sensitive to cisplatin and several groups have investigated
the influence of ERCC1 on resistance to platinum chemotherapy
(Ferry et al, 2000; Reed, 2005) and suggest that ERCC1 is a
good marker for cellular or clinical resistance to these drugs. In
ERCC1 mutant cells, however, the high cisplatin sensitivity
observed compared to other mutant cells which are equally
defective in the unhooking step of interstrand crosslink repair is
most likely due to a defect other than in excision repair (De Silva
et al, 2002).
It has previously been demonstrated that the repair of DNA ICLs
produced by cisplatin, measured by the technique of alkaline filter
elution, was reduced in human lymphocytes from normal
volunteers aged around 70 compared to those from volunteers
aged around 20 (Rudd et al, 1995). In the current study, the age
range of patients was from 45 to 91 and there was no correlation
between age and extent of repair in the newly diagnosed patient
tumour samples.
Platinum compounds are the most active agents in ovarian
cancer treatment and the decision to retreat recurrent disease with
platinum is based on clinical observations that have shown
the likelihood of response is dependent on the platinum-free
interval (Blackledge et al, 1989; Markman et al, 1991). The study of
ex vivo treatment of tumour samples from women with newly
diagnosed and relapsed ovarian cancer has identified biochemical
changes in the formation and repair of cisplatin-induced DNA
crosslinks that provide new information on some of the
mechanisms associated with resistance to platinum in patients
with ovarian cancer. Firstly, the ability of cisplatin to form DNA
crosslinks is similar in normal (mesothelial) and tumour tissue
and similar levels of crosslinking were seen in patients whose
tumours were exposed to in vitro cisplatin after a ‘platinum-free
interval’ of less than or greater than 6 months. Secondly, in
comparison to the platinum naı ¨ve group, there were marked
differences in the repair of platinum-induced crosslinks in tumour
cells removed at IDS or after relapse at a less than or greater than
6 months platinum-free period. In the previously treated group,
86% showed greater than 10% repair compared with 36% in
chemonaı ¨ve patients.
A Cox regression was used to examine the association between
progression-free survival and percentage DNA repair in the newly
diagnosed patient samples. There was no evidence of an
association (the hazard ratio for an increase of 1 percentage point
was 0.99, 95% CI 0.97–1.02, P-value¼0.56). No relationship was
therefore evident between repair of ICLs and inherent sensitivity.
In the case of treated patients, the number in each category (IDS,
platinum-free interval (PFI) 46 months, PFI o6 months) was too
small to perform the equivalent analysis.
The paired samples (Figure 5) allow further conclusions to
be drawn. In all four paired samples taken pre-treatment and then
at IDS there was an increased ability to repair platinum-induced
crosslinks after 3–4 cycles of platinum-based chemotherapy.
This suggests that significant changes in the tumour have
either developed, or become evident through selection after as
few as three cycles of chemotherapy. In three of these cases,
the outcome after chemotherapy and surgery was a complete
response, but relapse occurred between 4 and 12 months in all
four cases. As previously stated, the unhooking of DNA crosslinks
is only one of a number of events leading to repair and
contributing to clinical resistance. Even in a larger group of
patients, it is unclear whether this early change in the tumour
metabolism has clinically meaningful information. Similarly,
within the sub-group of clinical ‘platinum-sensitivity’ or ‘-
resistance’, it is difficult to draw conclusions about a relationship
of repair to progression-free survival on further treatment as the
number of patients per group is small and the treatment given at
relapse varied. Furthermore, the definition of platinum-sensitivity
is a clinical one and represents an empirically defined grouping of
patients, based on an observed probability of response to platinum
re-challenge. However, there is a consistent pattern within the
paired samples.
For the four patients with paired samples at relapse/progression,
a significant increase in repair was also seen compared to their
pre-treatment sample. Three patients were considered too
unwell for further treatment at this point but one (patient 39),
treated with cisplatin and etoposide had a partial response
lasting more than 4 months. Whilst this study does not assist
the clinical decision process about the choice of therapy for first
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sor subsequent line therapy, it clearly shows that changes in the
tumour metabolism of cisplatin-induced crosslinks evolve
quickly after platinum-based therapy and that the mechanisms
of clinical resistance are likely to involve the repair and
processing of DNA ICLs. The early appearance of these
differences merits further investigation in a larger number of
patients treated with platinum-based therapy to determine any
relationship between this enhanced DNA repair and clinical
outcome.
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